

15 May 2025

LungLife AI, Inc.
(the "Company" or "LungLife")

Block Admission Six Monthly Return

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block admission pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:

Name of Company:		LungLife AI, Inc.		
Name of scheme:		1. 2010 Stock Incentive Plan 2. 2020 Stock Incentive Plan 3. 2021 Omnibus Long-Term Incentive Plan		
Number and class of securities originally admitted:		1,356,139 common shares of US 0.0001 each		
Date of admission:		15 November 2021		
Period of return:	From:	15 November 2024	To:	15 May 2025
Balance of unallotted securities under scheme(s) from previous return:		1. 475,583 2. 201,374 3. 673,990		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		1. NIL 2. NIL 3. NIL		
Less: Number of securities issued/allotted under scheme(s) during period:		1. NIL 2. NIL 3. NIL		
Equals: Balance under scheme(s) not yet issued/allotted at end of period :		1. 475,583 2. 201,374 3. 673,990		
Total number of securities in issue at the end of the period		30,658,603		

Name of contact:		David Anderson, Chief Financial Officer		
Telephone number of contact:		+44 (0)20 7933 8780		

For further information please contact:

LungLife AI, Inc.
Paul Pagano, CEO
David Anderson, CFO

www.lunglifeai.com
via investors@lunglifeai.com

Allenby Capital Limited
Nominated Adviser and Joint Broker
Alex Brearley / Lauren Wright - Corporate Finance
Matt Butlin / Guy McDougall - Equity Sales & Corporate Broking

Tel: +44 (0)20 3328 5656
info@allenbycapital.com

Goodbody (Joint Broker)
Tom Nicholson / Cameron Duncan

Tel: +44 (0) 20 3841 6202

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com.

Our Purpose is to be a driving force in the early detection to lung cancer. And our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BLRFLFFREVISLIE